New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
05:27 EDTGSK, AGENGlaxo's Phase 3 Malaria Vaccine Candidate with Agenus' QS-21 shows efficacy
Agenus (AGEN) announced the second complete set of results from the Phase 3 trial of GlaxoSmithKline's (GSK) RTS,S malaria vaccine candidate -- also known as Mosquirix -- which contains Agenus' QS-21 Stimulon adjuvant, were published online in the New England Journal of Medicine and announced at the International Vaccines for Africa Conference in Cape Town, South Africa. QS-21 Stimulon is a component of AS01, one of GSK's proprietary adjuvant systems used in RTS,S. The Phase 3 study met its primary endpoint and demonstrates statistically significant protection against clinical and severe malaria in infants. Agenus is entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.
News For AGEN;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
11:29 EDTGSKStudy says Valeant, others exploding dermatology drug prices, WSJ reports
The JAMA Dermatology journal published a new study that found that retail prices of 19 dermatologic prescription drugs increased fivefold on average between 2009 and 2015, reported The Wall Street Journal. Targretin, marketed by Valeant (VRX), jumped to $30,320 this year from $15,708 last year and $1,687 in 2009, the study found, but "It's not just Valeant," said lead author Miranda Rosenberg. Prices for drugs made by GlaxoSmithKline (GSK) and Novartis (NVS) at least doubled or tripled over the same time frame, the report noted. Reference Link
November 24, 2015
11:16 EDTGSKAdaptimmune initiates Phase I/II trial of affinity enhanced T-cell therapy
Subscribe for More Information
November 23, 2015
08:08 EDTGSKIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
November 20, 2015
16:09 EDTAGENAgenus files to sell 7.76M shares of common stock for holders
Subscribe for More Information
November 19, 2015
08:46 EDTAGENAgenus to host research and development update
Research and Development Update to be held in New York on November 19 at 4 pm. Webcast Link
November 18, 2015
08:11 EDTGSKIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use